The activity, pharmacokinetics, pharmacodynamics, efficacy, safety, drug interactions, and dosage and administration of moxifloxacin are reviewed. Moxifloxacin is an oral 8-methoxyquinolone ...

Moxifloxacin (as HCl) 400mg/250mL; soln for IV infusion; latex- and preservative-free. Moxifloxacin inhibits topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial ...

Objective: To compare the real-life treatment of acute exacerbations of chronic bronchitis (AECBs) using moxifloxacin tablets or one of the oral macrolides azithromycin, clarithromycin or ...

Treatment availability and patient outcomes are critical issues for the pharmaceutical industry, particularly in eye care.

It can also make your skin sensitive to sunlight. Moxifloxacin is a tablet you take by mouth once a day, at about the same time every day, with or without food. Depending on the infection ...

Dropless cataract surgery eliminates postoperative eye drops, enhancing patient adherence and reducing complications like ...

Discover all the brand names or Trade names of generic drug called Moxifloxacin. This serves as a crucial reference for healthcare professionals, patients, caregivers, and anyone looking to ...

Citalopram (as HBr) 2mg/mL; sugar- and alcohol-free; peppermint flavor; contains parabens. The mechanism of action of citalopram HBr as an antidepressant is presumed to be linked to potentiation ...

These include levofloxacin (Levaquin; Johnson & Johnson), moxifloxacin (Avelox; Bayer/Merck) and linezolid (Zyvox; Pfizer), which are expected to lose patent protection in 2011, 2014 and 2016 ...

Table 1 TB drug candidates in clinical development Full size table The two furthest advanced of the seven clinical candidates are the 8-methoxy-fluoroquinolones gatifloxacin and moxifloxacin (see ...

First randomized placebo-controlled trial in NTM abscessusSymptom-based endpoints showed favorable improvement in frequency and severity of the most common symptomsMicrobiologic endpoints showed ...

The Global Tuberculosis Report highlights that TB resurges as the leading infectious killer, surpassing COVID-19 in 2023 — ...